Drugs / Anti-CD19-CAR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04100187 | Feb → Aug 2023 | leukemia | Kecellitics Biotech Company Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT02546739 | Mar 2021 → Mar 2022 | leukemia, lymphoma | Beijing Doing Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03455972 | Feb 2018 → Dec 2027 expected | — | The First Affiliated Hospital of Soochow University | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-10-13 | Gilead Sciences | Results Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells gilead.com ↗
Kite Pharma, Inc. , (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the publication in The Lancet of clinical results demonstrating the potential to treat relapsed or refractory acute lymphoblastic leukemia (ALL) with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. |
| 2014-08-25 | Gilead Sciences | Results Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI) gilead.com ↗
Of the seven evaluable chemotherapy-refractory DLBCL patients, six showed a response (four complete remissions and two partial remissions), and one had stable disease. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19-CAR | “participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0)” NCT03455972 ↗ |
| Modality | Cell therapy | “CD19 Chimeric Antigen Receptor (CAR) T-cells” NCT02546739 ↗ |
| Route | Intravenous | “participants will get the T cells through the IV within 3 days” NCT03455972 ↗ |
| Target | CD19 | “targeting CD19” NCT02546739 ↗ |